{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:47:22Z","timestamp":1777078042317,"version":"3.51.4"},"reference-count":17,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2025,12,24]]},"DOI":"10.18632\/oncotarget.28820","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:40:33Z","timestamp":1767012033000},"page":"848-857","source":"Crossref","is-referenced-by-count":0,"title":["Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors"],"prefix":"10.18632","volume":"16","author":[{"given":"Joel","family":"Ohana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uziel","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Devary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"8","author":"Hartley","year":"2020","journal-title":"Cancer Res"},{"key":"2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"17","author":"McCormick","year":"2017","journal-title":"Cell"},{"key":"3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"57","author":"Rapaport","year":"2019","journal-title":"Nature"},{"key":"4","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"18","author":"Sinha","year":"2009","journal-title":"J Immunol"},{"key":"5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"1","author":"Licona-Lim\u00f3n","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"35","author":"Wolchok","year":"2018","journal-title":"Science"},{"key":"7","first-page":"327","article-title":"NEROFE--a novel human hormone-peptide with anti-cancer activity","volume":"8","author":"Devary","year":"2010","journal-title":"J Exp Ther Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3892\/mco.2017.1453","article-title":"dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function","volume":"7","author":"Devary","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"e00436","DOI":"10.1016\/j.heliyon.2017.e00436","article-title":"ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant","volume":"3","author":"Yanagisawa","year":"2017","journal-title":"Heliyon"},{"key":"10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3892\/mco.2017.1505","article-title":"A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced\/metastatic solid tumors","volume":"8","author":"Devary","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"1","author":"van Endert","year":"2007","journal-title":"Nat Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"33353","DOI":"10.1038\/srep33353","article-title":"Identification of Doxorubicin as an Inhibitor of the IRE1\u03b1-XBP1 Axis of the Unfolded Protein Response","volume":"6","author":"Koong","year":"2016","journal-title":"Sci Rep"},{"key":"13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"2","author":"Lalezari","year":"2019","journal-title":"Nat Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.18632\/oncotarget.28467","article-title":"Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin","volume":"1","author":"Devary","year":"2023","journal-title":"Oncotarget"},{"key":"15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/carcin\/bgq160","article-title":"The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS","volume":"3","author":"Chen","year":"2010","journal-title":"Carcinogenesis"},{"key":"16","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.3892\/ol.2017.6076","article-title":"MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS","volume":"1","author":"Shang","year":"2017","journal-title":"Oncol Lett"},{"key":"17","first-page":"158","article-title":"MicroRNA-217 regulates KRAS and inhibits tumorigenesis in acute myeloid leukemia","volume":"1","author":"Liu","year":"2017","journal-title":"Mol Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:17:57Z","timestamp":1777076277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,24]]}},"alternative-id":["28820","41459907"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28820","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}